Customized dual-ligand conjugated lipid nanoparticle (LNP) development services for combined receptor targeting, ligand pair engineering, surface density optimization, and payload-compatible formulation screening.
Dual-ligand conjugated LNPs are lipid nanoparticle delivery systems that display two distinct targeting ligands on the same particle, allowing them to engage two different receptors or receptor populations at once. By combining two ligand specificities—e.g., a sugar and a peptide, an antibody and a small molecule, or a targeting peptide and a cell-penetrating peptide—dual-ligand LNPs can address limitations that single-ligand designs often run into, including low uptake, narrow cell coverage, weak avidity, and competition with endogenous ligands.
The two ligands can recognize independent receptors on the same cell, two receptors on neighboring cells, or one receptor together with a transport pathway such as the blood–brain barrier (BBB) or a tissue-penetrating route. Rational pairing of ligands, linker chemistry, and surface density allows dual-ligand LNPs to improve receptor engagement, support heterogeneous cell populations, and open delivery options that are hard to access with single-ligand designs.
BOC Sciences supports pharmaceutical and biotechnology researchers developing dual-ligand LNPs for siRNA, mRNA, circRNA, guide RNA/mRNA complexes, proteins, peptides, small molecules, and imaging payloads. Our services cover ligand pair selection, dual-ligand synthesis, nanoparticle-conjugation route design, surface density optimization, core formulation integration, physicochemical characterization, and combined-receptor functional delivery evaluation.
Dual-Ligand Functionalized LNP Structure Illustration
BOC Sciences supports the full dual-ligand LNP development workflow, from ligand pair selection and surface modification, to LNP preparation, characterization, and combined-receptor targeting evaluation.
We help select and prepare two ligand–lipid conjugates that can be co-assembled or post-coupled on a single LNP. The selection considers receptor biology, ligand compatibility, steric interactions, and conjugation chemistry.
We tune the surface display of both ligands together, rather than optimizing each separately. The ratio, total ligand density, and display geometry are matched to receptor expression levels on the target cells.
Two ligands on the same LNP change particle assembly, surface charge, payload loading, and colloidal stability. We optimize the core formulation and the dual-ligand surface layer together.
We characterize dual-ligand LNPs to confirm particle quality, dual-ligand incorporation, payload retention, and formulation consistency. These data give clients clear decision points when comparing candidates.
We evaluate whether dual-ligand display improves binding, uptake, and payload function in relevant cell models, with control groups that help separate the contribution of each ligand from the combined effect.
BOC Sciences helps move dual-ligand LNP candidates into a reproducible preparation process, supporting consistent ligand display, payload loading, and particle quality across batches.
Dual-ligand LNPs work best when the two ligands are chosen with a clear delivery purpose—two receptors on the same cell, two subpopulations of target cells, or a targeting ligand plus a tissue-penetrating ligand. BOC Sciences supports a wide range of ligand pairs, drawing on our experience with single-ligand platforms such as mannose-conjugated LNPs, folate-conjugated LNPs, transferrin-conjugated LNPs, GalNAc-conjugated LNPs, peptide-functionalized LNPs, and antibody-conjugated LNPs.
Two sugar ligands on one particle, allowing co-engagement of two different C-type lectin receptors or two receptor populations. This format works well for immune-cell delivery and liver-asialoglycoprotein-receptor-related targeting.
Two peptides on one LNP, where each peptide recognizes a distinct receptor or a receptor and a tissue-penetrating route. Peptide pairs are easy to scale and have flexible chemistry for orthogonal display.
An antibody (or fragment) plus a sugar ligand, combining high-affinity protein recognition with low-immunogenicity sugar display. Useful when the antibody target alone gives narrow cell coverage.
A small-molecule ligand paired with a peptide ligand, combining synthetic chemical recognition with peptide-mediated binding.
A receptor-binding peptide plus a cell-penetrating peptide (CPP), separating the targeting step from the uptake step. This format helps particles reach intracellular compartments more reliably.
Projects often need something outside the standard pairs. BOC Sciences supports custom ligand combinations, scaffold designs, and non-standard receptor targets.
How the two ligands are placed on the LNP surface affects orientation, density, interference, and stability. BOC Sciences supports several conjugation routes so that the method matches the ligand pair, the payload, and the preparation workflow.
Both ligand–lipid conjugates are mixed with ionizable lipid, helper lipid, cholesterol, and PEG-lipid during LNP self-assembly, so the two ligands are inserted into the lipid layer as the particle forms.
A preformed LNP is mixed sequentially with two ligand–lipid micelles, so each ligand is inserted in a controlled order. Sequential insertion gives finer control over the density of each ligand on the final particle.
Both ligands are covalently attached to functional groups on the LNP surface using two bioorthogonal chemistries that do not interfere with each other. This route is preferred when the ligands cannot tolerate hydrophobic anchor insertion.
One ligand is incorporated during LNP self-assembly, and the second ligand is attached later through covalent coupling. It is useful when one ligand tolerates bilayer insertion while the other needs a covalent handle.
Develop dual-ligand LNPs with controlled ligand ratio, optimized surface display, payload-compatible formulation, and clear combined-receptor targeting performance.
Dual-ligand LNPs combine two receptor specificities on a single particle. Compared with single-ligand LNPs, dual-ligand LNPs can deliver stronger receptor binding through multivalent display, broader cell coverage across heterogeneous cell populations, and more reliable intracellular delivery when one ligand supports binding and the other supports uptake.
Improved Avidity Through Two Ligands
Two ligands on the same LNP allow cooperative binding. When the two receptors are co-expressed, the apparent affinity increases, which is especially useful in tumors with moderate receptor density.
Coverage of Heterogeneous Cell Populations
Real tumors and tissues rarely express a single receptor uniformly. Two ligands let a single LNP reach different subpopulations in the same tissue, reducing the risk that part of the target cell population is missed.
Separation of Targeting and Penetration Functions
One ligand can carry out the receptor-binding step, and the other can support penetration or intracellular delivery. This split design is hard to achieve with a single ligand, especially for tissues such as the brain.
Flexible Ligand Pair Engineering
The two ligands can be sugars, peptides, antibodies, small molecules, or a mix of these. This flexibility lets projects build delivery systems tailored to receptor biology rather than to the chemistry of a single ligand class.
BOC Sciences develops dual-ligand LNPs for many payload types used in combined receptor targeting research. Each payload needs a suitable loading strategy, particle design, and functional readout. We help match dual-ligand surface engineering with the payload type and the target-cell model, drawing on our lipid nanoparticle formulation capability and on related platforms such as co-encapsulation of multiple payloads in LNPs.
| Payload Type | Supported Uses & Dual-Ligand LNP Development Considerations | Request Information |
|---|---|---|
| Dual-Ligand LNP Development for siRNA | Suitable for dual-receptor gene-silencing studies, including receptor co-expression models, tumor heterogeneity research, and combined pathway knockdown. Development focuses on siRNA encapsulation, free RNA reduction, dual-ligand density, co-receptor uptake, and knockdown comparison using matched single-ligand and unmodified LNP controls. | Inquiry |
| Dual-Ligand LNP Development for mRNA and Reporter RNA | Designed for reporter expression, protein expression, antigen-related delivery, and dual-receptor targeting studies. Development considers mRNA integrity, encapsulation efficiency, dual-ligand surface exposure, particle stability, and expression readouts in receptor co-expression cell models. | Inquiry |
| Dual-Ligand LNP Development for circRNA and Self-Amplifying RNA | Applicable to RNA delivery systems that need strong payload protection and target-cell expression. BOC Sciences supports lipid nanoparticles for circRNA delivery with dual-ligand surface modification, stability evaluation, and cell-based expression testing. | Inquiry |
| Dual-Ligand LNP Development for gRNA/mRNA Combination | Supports co-loaded nucleic acid systems that need ratio control and particle uniformity. We evaluate co-encapsulation behavior, dual-ligand–lipid compatibility, particle attributes, and functional readouts in dual-receptor cell models. | Inquiry |
| Dual-Ligand LNP Development for Protein and Peptide | Suitable for protein antigens, enzymes, peptides, binding proteins, and functional protein payloads used in dual-receptor delivery research. Formulation work focuses on mild loading conditions, aggregation control, activity retention, and dual-ligand-dependent uptake evaluation. | Inquiry |
| Dual-Ligand LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules used in dual-receptor delivery research. We consider drug–lipid compatibility, loading method, leakage control, particle stability, dual-ligand modification, and release behavior. | Inquiry |
| Dual-Ligand LNP Development for Fluorescent and Imaging | Supports fluorescent dyes, labeled RNA, labeled proteins, and other tracking payloads used to study dual-ligand LNP uptake, intracellular localization, biodistribution trends, and dual-receptor formulation comparison. | Inquiry |
| Dual-Ligand LNP Development for Custom Payload | Developed for unusual payloads, multiple payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, dual-ligand route, particle stability, and dual-receptor delivery performance. | Inquiry |
Dual-ligand LNP development often fails when the two ligands interfere with each other, when encapsulation drops, or when PEG shielding blocks one of the ligands. BOC Sciences helps solve these problems with data-guided formulation, dual-ligand surface analysis, and matched single-ligand control LNPs.
✔ Insufficient Uptake from Single-Ligand Designs
A single ligand may give only modest uptake, especially when the receptor is expressed at a moderate level. We screen ligand pairs, surface densities, and linker designs so that two ligands working together can drive higher uptake than either ligand alone, supported by nanoparticle cellular uptake testing.
✔ Ligand–Ligand Interference During Co-Display
Two ligands on the same surface can crowd each other, fold over the binding site, or change orientation. We adjust ligand ratio, total surface density, PEG length, and scaffold architecture so that the two ligands do not block each other.
✔ Loss of Encapsulation Efficiency After Dual Modification
Two ligand–lipids consume more bilayer area than one, which can disturb self-assembly and reduce encapsulation. We re-balance ionizable lipid, helper lipid, cholesterol, and PEG-lipid content, then verify the formulation through our LNP encapsulation efficiency optimization workflow.
✔ PEG Masking of One or Both Ligands
PEG-lipid is often required for colloidal stability, but it can hide the ligands underneath. We tune PEG–lipid species, length, and content, drawing on our LNP PEG-lipid optimization experience, so that PEG stabilizes the particle without covering either ligand.
✔ Unclear Synergy vs. Additivity Between Two Ligands
It is hard to tell whether two ligands are working synergistically or just adding together. We design matched single-ligand and dual-ligand LNPs with the same total surface density, run them in the same cell model, and compare uptake and function side by side.
✔ Heterogeneous Cell Populations with Variable Receptor Expression
Real tissues mix receptor-high, receptor-low, and receptor-negative cells. We screen ligand pairs and ratios against mixed-population models so that the dual-ligand LNP can reach more cells than a single-ligand design.
BOC Sciences helps research teams troubleshoot ligand–ligand interference, encapsulation loss, PEG masking, dual-ligand surface analysis, combined-receptor uptake evaluation, and co-delivery workflow design.
We start by discussing the target receptor pair, the receptor co-expression profile, the payload type (RNA, protein, peptide, small molecule, imaging), the target cell model, and the expected readout. Based on these details, BOC Sciences prepares a practical dual-ligand LNP development plan.
We select a ligand pair that fits the receptor biology and a conjugation strategy that fits the chemistry of each ligand. This step covers ligand chemistry, linker length, lipid anchor, and the choice between co-assembly, post-insertion, orthogonal covalent coupling, or a hybrid route.
BOC Sciences prepares dual-ligand LNP candidates using suitable methods. We adjust lipid composition, payload loading, mixing conditions, buffer exchange, ligand ratio, total ligand density, and particle stability. Matched single-ligand and unmodified LNP controls can also be prepared for comparison.
Each dual-ligand LNP candidate is evaluated for particle size, PDI, zeta potential, payload loading, dual-ligand surface density, and formulation integrity. We can also support in vitro uptake, intracellular localization, reporter expression, gene silencing, and in vivo distribution-related readouts in suitable research models.
Dual-ligand LNPs are useful in research areas where a single targeting ligand is not enough, where the target cell population is heterogeneous, or where receptor-mediated binding alone does not guarantee intracellular delivery.
Challenge: A research team was developing an LNP to deliver siRNA into HER2+ breast cancer cells, but their single folate-LNP gave only about 30% knockdown in the cell model. The HER2 receptor was present on the cell surface, and the team wanted to combine receptor-mediated uptake with folate-receptor binding to improve functional delivery.
Diagnosis: BOC Sciences reviewed the formulation and found that folate-receptor density was moderate in the chosen cell model. A single ligand alone was not driving enough receptor-mediated uptake. The team also wanted to keep the LNP small enough for tumor penetration, which limited the total ligand density that could be placed on the surface.
Solution: BOC Sciences designed a dual-ligand LNP with an anti-HER2 antibody fragment and folate co-displayed on the same particle. The two ligands were conjugated through orthogonal chemistries (DBCO–azide for the antibody fragment, thiol–maleimide for the folate), then co-formulated with a standard ionizable lipid, helper lipid, cholesterol, and PEG-lipid system. We screened antibody fragment-to-folate ratios from 1:9 to 9:1 at matched total ligand density, and we compared the dual-ligand LNP with matched single-ligand and unmodified LNPs in the same HER2+ cell model. Each candidate was evaluated for particle size, PDI, zeta potential, dual-ligand surface density, siRNA encapsulation, HER2+ uptake, and gene knockdown.
Result: The selected antibody + folate dual-ligand LNP kept an average particle size of about 110 nm, with a PDI below 0.20 and siRNA encapsulation above 85%. In the HER2+ breast cancer cell model, the dual-ligand LNP showed about a 2.4-fold higher uptake than the folate-only LNP and reached about 75% target-gene silencing, compared with about 30% for the folate-only LNP. The client received a dual-ligand LNP candidate suitable for further HER2+ breast cancer delivery studies.
Challenge: A vaccine research group wanted to deliver self-amplifying mRNA into dendritic cells and macrophages. Their first mannose-only LNP gave measurable uptake in mannose-receptor-positive cells, but the mRNA expression level was low, especially in macrophages. The team needed a ligand combination that would reach more immune cell types without forcing high surface mannose density.
Diagnosis: BOC Sciences found that mannose-receptor density was high on dendritic cells but lower on macrophages, and that high mannose density alone reduced mRNA encapsulation. A second ligand that could engage a different receptor on the same immune cells would help both populations.
Solution: BOC Sciences designed a dual-ligand LNP co-displaying mannose (for mannose-receptor-positive cells) and a DC-targeting peptide (for dendritic cell co-receptors). The two ligands were anchored on PEG–DSPE lipids of different lengths to avoid mutual steric hindrance, with ligand ratios from 1:3 to 3:1 screened at matched total density. We prepared dual-ligand candidates, mannose-only controls, peptide-only controls, and unmodified LNPs, then evaluated particle size, PDI, dual-ligand surface density, mRNA integrity, encapsulation, immune-cell uptake, and mRNA expression.
Result: The optimized mannose + targeting peptide LNP kept the average particle size around 120 nm and maintained mRNA encapsulation above 75%. Uptake in dendritic cells and macrophages increased by about 1.8-fold and 2.3-fold compared with the mannose-only LNP, respectively. The client received a dual-ligand LNP candidate and a matched single-ligand comparator for further immune-cell delivery studies.
Broad Dual-Ligand Combination Capability
We support sugar + sugar, peptide + peptide, antibody + sugar, small molecule + peptide, targeting peptide + cell-penetrating peptide, and custom dual-ligand pairs, drawing on our experience with single-ligand platforms such as pegylated lipid nanoparticles and peptide-functionalized lipid nanoparticles.
Flexible Conjugation Chemistry Toolbox
We support co-assembly, sequential post-insertion, orthogonal covalent surface conjugation, and hybrid routes, so the conjugation chemistry fits the ligand pair and the payload rather than the other way around.
Quantitative Dual-Ligand Surface Analysis
Each ligand on the LNP surface is quantified separately, using ligand-specific binding assays, HPLC-FLD, or LC-MS/MS. This makes it possible to compare dual-ligand candidates with matched single-ligand controls.
Synergy-Designed Formulation Development
Dual-ligand LNP candidates are evaluated with matched single-ligand and unmodified LNPs in the same receptor co-expression model, so the contribution of each ligand and the combined effect can be separated.
Custom Project Support Across Discovery to Pilot Scale
BOC Sciences supports feasibility testing, formulation screening, ligand ratio optimization, process adjustment, control LNP preparation, and dual-receptor delivery evaluation for projects ranging from early discovery to pilot batch preparation.
Dual-ligand LNPs are particularly useful when two distinct biological interactions are relevant to the intended delivery route. For example, one ligand may recognize a receptor associated with the desired cell population, while a second ligand binds another receptor or promotes cellular internalization. This approach may help address variable receptor expression or targeting limitations observed with single-ligand formulations. However, adding a second ligand also increases surface complexity and may affect particle stability or ligand accessibility. Researchers should compare unmodified, single-ligand, and dual-ligand LNPs under matched experimental conditions, evaluating both receptor-dependent uptake and functional payload delivery to determine whether the additional ligand provides a meaningful advantage.
Optimizing dual-ligand density requires controlling the surface concentration and accessibility of each ligand rather than simply increasing total ligand content. Researchers can screen different ligand A-to-B ratios, PEG spacer lengths, lipid anchors, and conjugation sequences while maintaining comparable core formulations. Analytical methods such as LC-MS, fluorescence-based assays, and ligand-specific receptor binding measurements can help quantify incorporation and accessible surface display. Excessive ligand density may cause steric interference, particle aggregation, or reduced payload retention. Therefore, the optimal combination should be selected based on physicochemical characterization, ligand-specific binding, receptor-dependent cellular uptake, and functional delivery performance rather than ligand density alone.
Demonstrating synergy requires more than observing increased cellular uptake after introducing a second ligand. A suitable experimental design should include unmodified LNPs, ligand A-only LNPs, ligand B-only LNPs, and dual-ligand LNPs with comparable particle properties and payload doses. Receptor-blocking experiments, competitive binding assays, and receptor-high versus receptor-low cell models can help determine the contribution of each ligand. Functional endpoints such as reporter expression, gene silencing, or intracellular payload activity should also be measured. To distinguish genuine synergy from additive effects, researchers should compare the observed dual-ligand response with an appropriate predefined additive-effect model using quantitative dose-response data and replicate experiments.
BOC Sciences provides customized dual-ligand LNP development services covering ligand selection, conjugate synthesis, surface modification, formulation optimization, and functional characterization. We support various combinations, including sugar-sugar, peptide-peptide, antibody-sugar, small molecule-peptide, and targeting peptide-cell-penetrating peptide systems. Depending on ligand chemistry and payload requirements, our scientists can develop co-assembly, sequential post-insertion, orthogonal covalent conjugation, or combined modification strategies. We also support PEG spacer selection, lipid anchor design, independent ligand density optimization, and ligand-specific surface analysis. These capabilities allow researchers to explore different dual-ligand architectures and identify formulation strategies suited to their target receptors and research objectives.
BOC Sciences helps researchers investigate challenges arising during dual-ligand LNP design, preparation, characterization, and functional evaluation. Common problems include ligand-ligand interference, PEG masking, insufficient receptor-dependent uptake, reduced encapsulation efficiency, particle instability, and limited improvement over single-ligand formulations. Our scientists can review existing formulation data, assess ligand compatibility, optimize surface ratios and conjugation sequences, and adjust core lipid compositions where necessary. We also support ligand-specific characterization, receptor-binding studies, cellular uptake analysis, and functional payload evaluation using appropriate controls. Clients can share their proposed ligand combinations, payload specifications, target-cell models, or existing experimental results to discuss a customized troubleshooting and development strategy.
